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 Atherosclerotic cardiovascular disease (ASCVD) remains a significant cause of 
morbidity and mortality in women, with the event rates particularly rising in young women. 
Women are disproportionately affected by traditional cardiovascular (CV) risk factors such as 
diabetes and hypertension compared with men. In addition to standard risk factors, there are 
many risk factors that are either female predominant, such as autoimmune conditions and 
psychological stressors, or female specific, such as hormonal changes, throughout the course of a 
lifetime and pregnancy-related issues. Among the most important risk factors specific to women 
are conditions occurring during pregnancy and history related to fertility and gynecologic 
conditions. The value of such history has become more apparent in recent literature, however the 
translation of this knowledge to clinical practice has been poor. The importance of recognizing 
specific obstetric and gynecologic conditions and the specific conditions to screen for are the 
focus of this discussion. 
 
Obstetrics History 
Pregnancy is often referred to as a “stress test” in relation to the significant changes in 
cardiac output and associated heart rate/stroke volume that occur. There are also changes in 
metabolic regulation which, when dysfunctional, can lead to adverse neonatal and maternal 
outcomes. These conditions associated with long-term CV risk are collectively referred to as 
adverse pregnancy outcomes (APO) and are listed in the Figure (1). APOs, including 
hypertensive disorders of pregnancy (HDP) and gestational diabetes, have been associated with 
elevated risk of CV events including myocardial infarction, heart failure, and stroke. Neonatal 
outcomes such as spontaneous preterm birth and intrauterine growth restriction are not only 
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associated with adverse infant outcomes, but also adverse long-term maternal CV outcomes. It is 
unknown whether the association between APO and ASCVD risk is due to underlying 
predisposition to ASCVD or whether pregnancy triggers onset of vascular dysfunction (Figure). 
However, what has become more readily evident is that APO not only leads to peri-partum 
neonatal and maternal adverse outcomes but is associated with significant long-term ASCVD 
risk. In this case, it is of the utmost importance to recognize such history so that proper screening 
and potential risk modification can be implemented. In the US, over 80% of women experience 
at least one pregnancy. Documenting such history provides insight into risk and the results of this 
“free” stress test can be obtained without cost by simply asking women about their obstetric 
history. Maternal recollection of events during their pregnancy has been shown to be an accurate 
reflection of their obstetric history. Recent multi-disciplinary society guidelines have 
acknowledged the importance of recognizing APOs in evaluating, identifying and potentially 
modifying, ASCVD risk (2). ACOG guidelines recommend routine screening of BMI, lipids, and 
blood pressure in all women with history of APO (3). Newly released AHA/ACC guidelines on 
blood cholesterol now include APOs as potential “risk enhancers” in consideration of ASCVD 
risk. Even among women without APOs, parity in of itself has been associated with ASCVD risk 
in that parous women compared with nulliparous women exhibit greater ASCVD risk, which 
increases proportionally to each live birth. Obtaining a cardio-obstetric history is critically 
important to accurately assessing ASCVD risk, when women otherwise might appear to be low-
risk for ASCVD.  
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Infertility and Assisted Reproductive Technology 
Discussion of reproductive history should also include assessment of history of recurrent 
miscarriage, infertility conditions, and use of assisted reproductive technology (ART). There is 
some evidence suggesting recurrent miscarriage (3 consecutive miscarriages) is associated with 
ASCVD, and optimization of modifiable ASCVD risk factors in women with this history is 
recommended. Polycystic ovary syndrome (PCOS) is a common cause of infertility affecting 5-
10% of women. PCOS is associated with increased risk of hypertension, dyslipidemia, 
gestational diabetes, and type 2 diabetes, thus allowing opportunities for risk screening and 
modification. Therefore, in women with PCOS, the ESC and ACOG guidelines have 
recommended periodic screening for diabetes and ASCVD risk factors, respectively. ART, 
which includes intrauterine insemination and in vitro fertilization, has been associated with 
elevated risk of gestational hypertension, pre-eclampsia, and APOs. The mechanism is unclear 
but may be mediated through excessive fluid shifts in the setting of ovarian activation (referred 
to as ovarian hyperstimulation syndrome) and/or hormone-related effects on endothelial 
function. Although a meta-analysis on this subject concluded no significant association between 
ART and CVD risk, this analysis was composed of only six studies and could not make a 
definitive assessment of long-term venous thromboembolic risk, and also suggested an increased 
risk of stroke. Furthermore, failure to conceive following ovulation induction as part of ART has 
been associated with increased ASCVD risk. As such, care should be taken to inquire about ART 
history while further studies investigate this potential association.  
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Hormonal Therapy 
 Several gynecologic conditions that affect fertility and menopause have been associated 
with increased risk of ASCVD. It is known that the risk of ASCVD increases following 
menopause. Similarly, surgical menopause and premature ovarian insufficiency (POI) are 
associated with increased risks of CVD. POI occurs in approximately 1% of the female 
population, and current AHA/ACC, ESC, and Dutch guidelines all recommend optimizing 
modifiable ASCVD risk factors in this high-risk group. As hormone replacement therapy (HRT) 
in post-menopausal women is linked to increased risks of stroke and venous thromboembolism, 
for women with surgical menopause and POI, HRT should only continue until the average age of 
menopause. Combined oral contraceptive pills that contain estrogen are associated with 
increased risk of venous thromboembolism, and are contraindicated in women with ischemic 
heart disease, cyanotic heart disease, heart failure, or arrhythmia, and in those with pulmonary 
hypertension taking endothelin receptor antagonists. Contraceptive methods for women with 
cardiac disease is a delicate issue that deserves special consideration but is outside the scope of 
this review article.  
 
Future Directions 
As the value of screening for female-specific risk factors related to obstetric and 
gynecologic history is more widely recognized to better assess ASCVD risk, the next question is 
which providers should be screening for such conditions. In the immediate postpartum period it 
is imperative that women with HDP have close follow up to assess adequate blood pressure 
control. Developing a system to transition such women to regular follow up with a primary care 
physician or cardiologist is key to avoid gaps in care. A recommended list of obstetric and 
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gynecologic conditions to screen for is presented in the Table. Automated referral systems post 
delivery and facilitating visits at hospital discharge can alleviate attrition in postpartum follow 
up. For the long term, as many of these young women of childbearing age often do not have 
other chronic medical conditions, they may not routinely seek primary care. However, a key 
opportunity for screening is within obstetric and gynecological (OB-GYN) office visits. A 
significant number of women rely on OB-GYN providers as their primary care provider. Such 
visits provide a valuable opportunity to screen women for ASCVD risk factors and also utilize 
OB-GYN history for either implementation of screening or risk reduction and/or referral to a 
primary care physician or cardiologist (2). Such an initiative was put forth through a partnership 
between SCAI-WIN and ACC in 2012, demonstrating proof of concept for improving risk 
assessment and referral. Education also needs to be highlighted within primary care specialties 
where primary prevention can be implemented in young women. Innovative approaches to 
bridging gaps in care such as this are needed to capture women who are at risk. 
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Table. Recommended adverse pregnancy outcomes and gynecologic conditions for 
cardiovascular disease risk screening 
 
Pregnancy history   
Hypertensive disorders of pregnancy 
      Gestational hypertension 
      Pre-eclampsia 
      Eclampsia 
      Chronic hypertension 
Gestational diabetes  
Preterm birth (<37 weeks)  
Intrauterine growth restriction/low birth weight/small for gestational age  
Parity 
Miscarriages 
Assisted reproductive technology  
Infertility 
 
Gynecologic history 
Polycystic ovarian syndrome 
Premature ovarian insufficiency 
Use of oral contraceptives 
Menopausal status 
Use of hormone replacement therapy 
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FIGURE  
 
Figure. Potential mechanisms for the association between adverse pregnancy outcomes and 
future cardiovascular disease risk. CHD = coronary heart disease; CVA = cerebrovascular 
accident; CVD = cardiovascular disease. 
Reprinted from Wu P, Mamas MA, Gulati M. Pregnancy as a predictor of maternal 
cardiovascular disease: The era of cardioobstetrics. J Womens Health (Larchmt). 2019;28:1037-
50. Copyright 2019 by Mary Ann Liebert, Inc. New Rochelle, NY. Reprinted with permission. 
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